Cell transfer-based immunotherapies in cancer: A review.

Autor: Gorabi AM; Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Hajighasemi S; Faculty of Paramedicine, Department of Medical Biotechnology, Qazvin University of Medical Sciences, Qazvin, Iran., Sathyapalan T; Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK., Sahebkar A; Halal Research Center of IRI, FDA, Tehran, Iran.; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Jazyk: angličtina
Zdroj: IUBMB life [IUBMB Life] 2020 Apr; Vol. 72 (4), pp. 790-800. Date of Electronic Publication: 2019 Oct 21.
DOI: 10.1002/iub.2180
Abstrakt: In cell transfer therapy (CTT), immune cells such as innate immune-derived natural killer cells and dendritic cells as well as acquired immune-related T lymphocytes such as tumor-infiltrating lymphocytes and cytokine-activated or genetically modified peripheral blood T cells are used in the management of cancer. These therapies are increasingly becoming the most used treatment modality in cancer after tumor resection, chemotherapy, and radiotherapy. In adoptive cell transfer, the lymphocytes isolated from either a donor or the patient are modified ex vivo and reinfused to target malignant cells. Transferring in vitro-manipulated immune cells produces a continuous antitumor immune response. In this review, we evaluate the recent advances in CTT for the management of various malignancies.
(© 2019 International Union of Biochemistry and Molecular Biology.)
Databáze: MEDLINE
Externí odkaz: